Best Biotech Stocks To Consider – February 03rd

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are publicly traded companies that focus on the development, production, and commercialization of products based on biological and medical research. These stocks are typically associated with companies in the fields of pharmaceuticals, genetics, medical devices, and other healthcare-related industries. Investors often consider biotech stocks to be high-risk, high-reward opportunities due to the volatile nature of the industry and the potential for significant gains or losses. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded up $5.50 during midday trading on Monday, hitting $189.40. The stock had a trading volume of 3,805,959 shares, compared to its average volume of 6,092,297. The company’s 50-day moving average price is $176.57 and its 200-day moving average price is $185.13. The company has a market capitalization of $334.70 billion, a P/E ratio of 78.90, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. AbbVie has a fifty-two week low of $153.58 and a fifty-two week high of $207.32.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of NASDAQ:VRTX traded up $5.13 during midday trading on Monday, hitting $466.81. The stock had a trading volume of 931,761 shares, compared to its average volume of 1,551,995. The company’s 50-day moving average price is $434.55 and its 200-day moving average price is $462.75. The company has a market capitalization of $120.22 billion, a P/E ratio of -234.39, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE:TMO traded down $2.15 during midday trading on Monday, hitting $595.61. The stock had a trading volume of 687,376 shares, compared to its average volume of 2,043,487. The company’s 50-day moving average price is $541.37 and its 200-day moving average price is $571.18. The company has a market capitalization of $227.82 billion, a P/E ratio of 36.03, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77. Thermo Fisher Scientific has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.